SH229

DRUG2 trials

Sponsors

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Conditions

Drug InteractionsHCV Infection

Phase 1

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

CompletedNCT03588923

Nanjing Sanhome Pharmaceutical, Co., Ltd.HCV Infection

Start: 2018-07-07End: 2018-08-10Updated: 2018-08-28

A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

CompletedNCT03748745

Nanjing Sanhome Pharmaceutical, Co., Ltd.Drug Interactions

Start: 2018-11-19End: 2018-12-25Updated: 2019-08-13